Total No. of patients | ||
Characteristics | study group | reference group |
Male sex | 40 (78.4%) | 37 (67.3%) |
Female sex | 11 (21.6%) | 18 (32.7%) |
Age-yr | 65.7 ± 12.2 | 65.3 ± 12.6 |
Coronary artery disease | ||
Known | 15 (29.4%) | 11 (20.0%) |
No | 35 (68.6%) | 40 (72.7%) |
Unknown | 1 (2.0%) | 4 (7.3%) |
Hypertension | ||
Known | 34 (66.7%) | 32 (58.2%) |
No | 15 (29.4%) | 20 (36.4%) |
Unknown | 2 (3.9%) | 3 (5.5%) |
Hypercholesterolemia | ||
Known | 29 (56.9%) | 28 (50.9%) |
No | 14 (27.5%) | 22 (40.0%) |
Unknown | 8 (15.7%) | 5 (9.1%) |
Diabetes mellitus | ||
Known | 11 (21.6%) | 13 (23.6%) |
No | 35 (68.6%) | 40 (72.7%) |
Unknown | 5 (9.8%) | 2 (3.6%) |
Nicotine abuse | ||
Yes | 27 (52.9%) | 23 (41.8%) |
No | 21 (41.2%) | 30 (54.5%) |
Unknown | 3 (5.9%) | 2 (3.6%) |
Acetylsalicylic acid | ||
Use | 18 (35.3%) | 21 (38.2%) |
No use | 30 (58.8%) | 33 (60.0%) |
Unknown use | 3 (5.9%) | 1 (1.8%) |
Beta-adrenergic blockers | ||
Use | 16 (31.4%) | 18 (32.7%) |
No use | 31 (60.8%) | 35 (63.6%) |
Unknown use | 4 (7.8%) | 2 (3.6%) |
ACE-blockers | ||
Use | 20 (39.2%) | 16 (29.1%) |
No use | 27 (52.9%) | 36 (65.5%) |
Unknown use | 4 (7.8%) | 3 (5.5%) |
Statin | ||
Use | 15 (29.4%) | 17 (30.9%) |
No use | 32 (62.7%) | 36 (65.5%) |
Unknown use | 4 (7.8%) | 2 (3.6%) |